Global IgA Nephropathy Treatment Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global IgA Nephropathy Treatment Market Research Report 2024
Currently, there are two main methods for the treatment of IgA nephropathy, one is conservative therapy and the other is immunosuppressive therapy.
According to Mr Accuracy reports new survey, global IgA Nephropathy Treatment market is projected to reach US$ 50 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 19.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole IgA Nephropathy Treatment market research.
Clearances and approval of new drugs, as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups, will have a positive impact on the market growth. For instance, US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.
Growing health consciousness coupled with high per capita disposable income is significantly contributing to the market growth. According to a nationwide study published in the Journal of the American Society of Nephrology, the incidence rate of IgA nephropathy (IgAN) is estimated to be 2-10 per 100,000 individuals a year.
The USA is at high risk for such diseases due to the growing number of chronic diseases and a sedentary lifestyle. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults. As per the report by the Centers for Disease Control and Prevention (CDC) on chronic kidney disease in the United States, in 2021, there are about 37 million people affected by chronic kidney diseases.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global IgA Nephropathy Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AstraZeneca
Johnson & Johnson Private Limited
Cipla Inc.
Hikma Pharmaceuticals PLC
Zydus Cadila
LEO Pharma A/S
Fresenius Kabi AG
Accord Healthcare
Abbott
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Alembic Pharmaceuticals Limited
Apotex Inc
Eldon Pharmaceutical
Segment by Type
Corticosteroids
Immunosuppressant
ACE and ARB Inhibitors
Hospital
Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The IgA Nephropathy Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global IgA Nephropathy Treatment market is projected to reach US$ 50 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 19.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole IgA Nephropathy Treatment market research.
Clearances and approval of new drugs, as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups, will have a positive impact on the market growth. For instance, US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.
Growing health consciousness coupled with high per capita disposable income is significantly contributing to the market growth. According to a nationwide study published in the Journal of the American Society of Nephrology, the incidence rate of IgA nephropathy (IgAN) is estimated to be 2-10 per 100,000 individuals a year.
The USA is at high risk for such diseases due to the growing number of chronic diseases and a sedentary lifestyle. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults. As per the report by the Centers for Disease Control and Prevention (CDC) on chronic kidney disease in the United States, in 2021, there are about 37 million people affected by chronic kidney diseases.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global IgA Nephropathy Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Johnson & Johnson Private Limited
Cipla Inc.
Hikma Pharmaceuticals PLC
Zydus Cadila
LEO Pharma A/S
Fresenius Kabi AG
Accord Healthcare
Abbott
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Alembic Pharmaceuticals Limited
Apotex Inc
Eldon Pharmaceutical
Segment by Type
Corticosteroids
Immunosuppressant
ACE and ARB Inhibitors
Segment by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The IgA Nephropathy Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices